Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland

Stuart J McGurnaghan, Amanda Weir, Jen Bishop, Sharon Kennedy, Luke A K Blackbourn, David A McAllister, Sharon Hutchinson, Thomas M Caparrotta, Joseph Mellor, Anita Jeyam, Joseph E O'Reilly, Sarah H Wild, Sara Hatam, Andreas Höhn, Marco Colombo, Chris Robertson, Nazir Lone, Janet Murray, Elaine Butterly, John Petrie, Brian Kennon, Rory McCrimmon, Robert Lindsay, Ewan Pearson, Naveed Sattar, John McKnight, Sam Philip, Andrew Collier, Jim McMenamin, Alison Smith-Palmer, David Goldberg, Paul M McKeigue, Helen M Colhoun, Public Health Scotland COVID-19 Health Protection Study Group, Scottish Diabetes Research Network Epidemiology Group, Alice Whettlock, Allan McLeod, Andrew Gasiorowski, Andrew Merrick, Andy McAuley, April Went, Calum Purdie, Colin Fischbacher, Colin Ramsey, David Bailey, David Henderson, Eisin McDonald, Genna Drennan, Graeme Gowans, Graeme Reid, Heather Murdoch, Jade Carruthers, Josie Murray, Karen Heatlie, Lorraine Donaldson, Martin Paton, Martin Reid, Melissa Llano, Michelle Murphy-Hall, Ross Hall, Ross Cameron, Susan Brownlie, Adam Gaffney, Aynsley Milne, Christopher Sullivan, Edward McArdle, Elaine Glass, Johanna Young, William Malcolm, Jodie McCoubrey, Stuart J McGurnaghan, Amanda Weir, Jen Bishop, Sharon Kennedy, Luke A K Blackbourn, David A McAllister, Sharon Hutchinson, Thomas M Caparrotta, Joseph Mellor, Anita Jeyam, Joseph E O'Reilly, Sarah H Wild, Sara Hatam, Andreas Höhn, Marco Colombo, Chris Robertson, Nazir Lone, Janet Murray, Elaine Butterly, John Petrie, Brian Kennon, Rory McCrimmon, Robert Lindsay, Ewan Pearson, Naveed Sattar, John McKnight, Sam Philip, Andrew Collier, Jim McMenamin, Alison Smith-Palmer, David Goldberg, Paul M McKeigue, Helen M Colhoun, Public Health Scotland COVID-19 Health Protection Study Group, Scottish Diabetes Research Network Epidemiology Group, Alice Whettlock, Allan McLeod, Andrew Gasiorowski, Andrew Merrick, Andy McAuley, April Went, Calum Purdie, Colin Fischbacher, Colin Ramsey, David Bailey, David Henderson, Eisin McDonald, Genna Drennan, Graeme Gowans, Graeme Reid, Heather Murdoch, Jade Carruthers, Josie Murray, Karen Heatlie, Lorraine Donaldson, Martin Paton, Martin Reid, Melissa Llano, Michelle Murphy-Hall, Ross Hall, Ross Cameron, Susan Brownlie, Adam Gaffney, Aynsley Milne, Christopher Sullivan, Edward McArdle, Elaine Glass, Johanna Young, William Malcolm, Jodie McCoubrey

Abstract

Background: We aimed to ascertain the cumulative risk of fatal or critical care unit-treated COVID-19 in people with diabetes and compare it with that of people without diabetes, and to investigate risk factors for and build a cross-validated predictive model of fatal or critical care unit-treated COVID-19 among people with diabetes.

Methods: In this cohort study, we captured the data encompassing the first wave of the pandemic in Scotland, from March 1, 2020, when the first case was identified, to July 31, 2020, when infection rates had dropped sufficiently that shielding measures were officially terminated. The participants were the total population of Scotland, including all people with diabetes who were alive 3 weeks before the start of the pandemic in Scotland (estimated Feb 7, 2020). We ascertained how many people developed fatal or critical care unit-treated COVID-19 in this period from the Electronic Communication of Surveillance in Scotland database (on virology), the RAPID database of daily hospitalisations, the Scottish Morbidity Records-01 of hospital discharges, the National Records of Scotland death registrations data, and the Scottish Intensive Care Society and Audit Group database (on critical care). Among people with fatal or critical care unit-treated COVID-19, diabetes status was ascertained by linkage to the national diabetes register, Scottish Care Information Diabetes. We compared the cumulative incidence of fatal or critical care unit-treated COVID-19 in people with and without diabetes using logistic regression. For people with diabetes, we obtained data on potential risk factors for fatal or critical care unit-treated COVID-19 from the national diabetes register and other linked health administrative databases. We tested the association of these factors with fatal or critical care unit-treated COVID-19 in people with diabetes, and constructed a prediction model using stepwise regression and 20-fold cross-validation.

Findings: Of the total Scottish population on March 1, 2020 (n=5 463 300), the population with diabetes was 319 349 (5·8%), 1082 (0·3%) of whom developed fatal or critical care unit-treated COVID-19 by July 31, 2020, of whom 972 (89·8%) were aged 60 years or older. In the population without diabetes, 4081 (0·1%) of 5 143 951 people developed fatal or critical care unit-treated COVID-19. As of July 31, the overall odds ratio (OR) for diabetes, adjusted for age and sex, was 1·395 (95% CI 1·304-1·494; p<0·0001, compared with the risk in those without diabetes. The OR was 2·396 (1·815-3·163; p<0·0001) in type 1 diabetes and 1·369 (1·276-1·468; p<0·0001) in type 2 diabetes. Among people with diabetes, adjusted for age, sex, and diabetes duration and type, those who developed fatal or critical care unit-treated COVID-19 were more likely to be male, live in residential care or a more deprived area, have a COVID-19 risk condition, retinopathy, reduced renal function, or worse glycaemic control, have had a diabetic ketoacidosis or hypoglycaemia hospitalisation in the past 5 years, be on more anti-diabetic and other medication (all p<0·0001), and have been a smoker (p=0·0011). The cross-validated predictive model of fatal or critical care unit-treated COVID-19 in people with diabetes had a C-statistic of 0·85 (0·83-0·86).

Interpretation: Overall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history.

Funding: None.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Risk of fatal or critical care unit-treated COVID-19 in the national population of Scotland with and without diabetes by age band and sex by July 31, 2020 Solid lines represent people with diabetes and dashed lines represent people without diabetes. Error bars indicate 95% CIs.
Figure 2
Figure 2
Weekly deaths from all causes and causes other than COVID-19 in people with diabetes in Scotland during 2020 compared with average deaths in that week from 2015–19 Dates denote the start of each 7-day interval. The difference between the deaths in 2020 and average deaths in 2015–19 is excess deaths during that period. The grey zone depicts how many deaths were attributable to COVID-19.

References

    1. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36
    1. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92:797–806.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
    1. Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R. Characteristics and outcomes of a cohort of COVID-19 patients in the province of Reggio Emilia, Italy. PLoS One. 2020;15
    1. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–2059.
    1. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612–1614.
    1. Centers for Disease Control Coronavirus disease 2019 (COVID-19)
    1. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369
    1. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382:2431–2440.
    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436.
    1. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, et al. Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. J Clin Endocrinol Metab. 2020;105
    1. Holman N, Knighton P, Kar P, et al. Type 1 and type 2 diabetes and COVID-19 related mortality in England: a cohort study in people with diabetes. Lancet Diabetes Endocrinol. 2020;8:823–833.
    1. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–822.
    1. UK National Health Service Who's at higher risk from coronavirus (COVID-19)
    1. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500–1515.
    1. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313:37–44.
    1. McAllister DA, Read SH, Kerssens J, et al. Incidence of hospitalization for heart failure and case-fatality among 3·25 million people with and without diabetes mellitus. Circulation. 2018;138:2774–2786.
    1. Scottish Government Scottish index of multiple deprivation.
    1. National Records of Scotland Scottish mid-year population estimates.
    1. R Core Team A language and environment for statistical computing.
    1. Honaker J, King G, Blackwell M. Amelia II: a program for missing data. J Stat Softw. 2011;45
    1. Ambler, original by Gareth and Benner, modified by Axel. Mfp: multivariable fractional polynomials.
    1. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28:964–974.
    1. McKeigue P. Quantifying performance of a diagnostic test as the expected information for discrimination: relation to the C-statistic. Stat Methods Med Res. 2018;28:1841–1851.
    1. Hamer M, Gale CR, Batty GD. Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: population-based, prospective cohort study. Metabolism. 2020;112
    1. McKeigue PM, Weir A, Bishop J, et al. Rapid epidemiological analysis of comorbidities and treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study. PLoS Med. 2020;17
    1. Haitao T, Vermunt JV, Abeykoon J, et al. COVID-19 and sex differences: mechanisms and biomarkers. Mayo Clin Proc. 2020;95:2189–2203.
    1. Hernán MA, Robins JM. Chapman and Hall; Boca Raton: 2020. Causal inference: what if.
    1. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395:931–934.
    1. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371
    1. WHO Clinical management of COVID-19. May 27, 2020.

Source: PubMed

3
Sottoscrivi